Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman(The University of Texas MD Anderson Cancer Center), Ray McDermott(St. Vincent's University Hospital), Joseph L. Leach(Allina Health), Sara Lonardi(Istituto Oncologico Veneto), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Michael A. Morse(Duke Medical Center), Jayesh Desai(The Royal Melbourne Hospital), Andrew Hill(Trans Tasman Radiation Oncology Group), Michael D. Axelson(Bristol-Myers Squibb (United States)), Rebecca A. Moss(Bristol-Myers Squibb (United States)), Monica V. Goldberg(Bristol-Myers Squibb (United States)), Z. Alexander Cao(Bristol-Myers Squibb (United States)), Jean-Marie Ledeine(Bristol-Myers Squibb (Belgium)), Gregory A. Maglinte(Bristol-Myers Squibb (United States)), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Thierry André(Assistance Publique – Hôpitaux de Paris)
The Lancet Oncology
July 19, 2017
10.1016/s1470-2045(17)30422-9
Cited by 2,803Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis